Clinical trials
Anaplastic Large Cell Lymphoma, ALK-negative clinical trials
Below are recruiting anaplastic large cell lymphoma, alk-negative clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Birmingham, AlabamaAges 18–75 - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT06176690RecruitingPhase 1
Donor cell therapy for CD30-positive lymphomas
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
Houston, TexasAges 12–75 - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39 - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT03964480Recruiting
Registry for newly diagnosed peripheral T-cell lymphoma patients
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Stanford, CaliforniaAges 18 years+ - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07470996Recruiting
T-cell lymphoma treatment after first therapy fails
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT07624838Recruiting
Brentuximab vedotin plus chemotherapy for CD30+ T-cell lymphoma
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
A Coruña, A CoruñaAges 18 years+ - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07313943Recruiting
Study of PAX5-negative Hodgkin-like lymphomas
This study looks at a rare type of lymphoma that looks like Hodgkin lymphoma but lacks a protein called PAX5. The goal is to better understand and diagnose this condition, which can be hard to tell apart from other lymphomas.
TübingenAges 18 years+
Hear when a new Anaplastic Large Cell Lymphoma, ALK-negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for anaplastic large cell lymphoma, alk-negative?
- Yes. Clin2 currently lists 15 recruiting anaplastic large cell lymphoma, alk-negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a anaplastic large cell lymphoma, alk-negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a anaplastic large cell lymphoma, alk-negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.